Small Animal Imaging (In-Vivo) Market Size, Share, Growth, and Industry Analysis, By Type (Micro-MRI,Optical,Nuclear), By Application (Monitoring Treatment Response,Bio-distribution,Determining Drug/Target Engagement,Cancer Cell Detection,Biomarkers,Longitudinal Studies,Epigenetics), Regional Insights and Forecast to 2035

Small Animal Imaging (In-Vivo) Market Overview

The global Small Animal Imaging (In-Vivo) Market is forecast to expand from USD 2642.65 million in 2026 to USD 2891.85 million in 2027, and is expected to reach USD 5432.26 million by 2035, growing at a CAGR of 9.43% over the forecast period.

The global small animal imaging (in-vivo) market is an essential segment of the preclinical research ecosystem, supporting over 4,500 imaging systems worldwide across academic, biotech and pharmaceutical sites as of 2024. Approximately 78 % of those systems are deployed in North America and Europe, while Asia-Pacific accounts for about 22 %. Optical imaging systems represent nearly 42 % of modality installations, followed by nuclear and micro-MRI technologies. In 2024 more than 12,000 peer-reviewed preclinical studies referenced small animal imaging in their methodology, underscoring the growing role of imaging in drug discovery. The Small Animal Imaging (In-Vivo) Market Size is driven by technological innovation and expanding research pipelines.

In the United States the small animal imaging (in-vivo) market remains the largest national segment, comprising approximately 67 % of the North America regional share in 2024. More than 1,200 institutions and contract research organizations (CROs) operate in-vivo imaging facilities, and over 9,000 small animal studies referenced imaging modalities in U.S. research journals that year. About 54 % of newly installed imaging systems in the U.S. during 2024 were optical imaging platforms, while micro-MRI units represented roughly 18 % of new deployments. Government and university research grants awarded in imaging-enabled studies rose by 21 % compared to 2023, reflecting the strength of the U.S. segment in the Small Animal Imaging (In-Vivo) Market Analysis.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 42 % of global small animal imaging systems are optical imaging platforms as of 2024.
• Major Market Restraint: 23 % of preclinical imaging labs report limited availability of imaging contrast agents and probes.
• Emerging Trends: 35 % of new installations in 2024 combined two or more imaging modalities in a hybrid platform.
• Regional Leadership: North America held approximately 36 % of global device installations in 2023.
• Competitive Landscape: The top five imaging equipment firms account for around 52 % of total global unit shipments.
• Market Segmentation: Small animal models with weight under 500 g represent nearly 46 % of all imaging applications.
• Recent Development: Over 80 new product launches for small animal imaging systems were introduced between 2023 and 2025.

Small Animal Imaging (In-Vivo) Market Latest Trends

The Small Animal Imaging (In-Vivo) Market Market Report shows a marked shift toward multimodal imaging systems combining optical, nuclear and MRI technologies. In 2024 approximately 35 % of new instrument purchases included combined-modality features, enabling researchers to monitor anatomical, functional and molecular events within a single experiment. The proliferation of genetically engineered rodent models is driving demand: more than 6,400 new mouse and rat imaging studies were published globally in 2024, representing an 18 % increase over 2023.

Small Animal Imaging (In-Vivo) Market Dynamics

DRIVER

"Increased preclinical research and need for in-vivo imaging"

The main driver of the Small Animal Imaging (In-Vivo) Market Growth is the rising volume of preclinical research, particularly in oncology, neuroscience and immunology. In 2024 global pharmaceutical pipelines included over 19,000 active drug candidates and more than 4,000 in-vivo animal-model studies referenced imaging systems. About 78 % of biotechnology companies incorporated small animal imaging in their discovery workflows, and over 65 % of academic research centres upgraded systems between 2022 and 2024 to accommodate advanced imaging. The adoption of high-resolution modalities such as micro-MRI (installed in 18 % of new labs in 2024) underscores this shift. For the Small Animal Imaging (In-Vivo) Market Industry Analysis, the increased demand for non-invasive monitoring of treatment response and disease progression is a key factor.

RESTRAINT

"Limited availability of specialised imaging agents and high system cost"

A significant restraint in the Small Animal Imaging (In-Vivo) Market Market Research Report is the scarcity of validated imaging probes and the high entry cost for advanced systems. In 2024 approximately 23 % of labs reported delays in projects due to unavailability of contrast agents for specific applications. Systems combining modalities averaged over 12,000 installation hours in the first year of use, and around 41 % of smaller CROs flagged budget constraints when upgrading. Approximately 27 % of facilities indicated that maintenance costs increased by more than 15 % year-on-year due to complex imaging hardware. These factors restrict smaller research institutions from acquiring state-of-the-art imaging platforms.

OPPORTUNITY

"Growth in emerging markets and advancement in automation and AI"

The Small Animal Imaging (In-Vivo) Market Market Opportunities lie in emerging markets and in automation of imaging workflows. Asia-Pacific accounted for 22 % of installations in 2024 and is forecast to increase its share as emerging economies in China, India and Southeast Asia expand their biopharma research infrastructure. Automated imaging platforms reduced throughput time by 24 % in 2024 compared to manual systems, and AI-based image-analysis modules were incorporated in 29 % of new systems. Lab-automation partners and imaging OEMs are collaborating to offer end-to-end solutions including image acquisition, AI-analysis and data integration. This presents a sizeable opportunity for B2B suppliers in the Small Animal Imaging (In-Vivo) Market Insights.

CHALLENGE

"Ethical, regulatory and infrastructural constraints"

Implementing small animal imaging involves regulatory and ethical constraints that pose challenges within the Small Animal Imaging (In-Vivo) Market Industry Report. In 2024 around 19 % of labs reported project delays due to ethical-committee review cycles exceeding 90 days. Some regions recorded up to 17 % of total preclinical studies being postponed due to inadequate imaging infrastructure or lack of qualified operators. Deep-tissue imaging remains a technological challenge: resolution drops by up to 36 % for optical modalities when imaging depth exceeds 10 mm in rodents. Addressing these issues requires investment in training, infrastructure and ethics compliance, which many smaller organisations struggle to afford.

Small Animal Imaging (In-Vivo) Market Segmentation

The Small Animal Imaging (In-Vivo) Market Market segmentation by type—micro-MRI, optical and nuclear imaging—and by application—monitoring treatment response, bio-distribution, determining drug/target engagement, cancer cell detection, biomarkers, longitudinal studies and epigenetics—reveals distinct adoption patterns. Optical systems accounted for 42 % of installations in 2024, while small animals dominated 46 % of applications under 500 g. In application breakdown, bio-distribution studies led with roughly 31 % share globally. Each segment offers unique demand drivers and investment profiles for stakeholders.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Micro-MRI : Micro-MRI systems represented about 18 % of small animal imaging equipment installed globally in 2024. These high-field MRI platforms operate at 7 Tesla or higher and support spatial resolution down to 100 micrometers, enabling detailed anatomical and functional imaging in rodent models. In 2024 more than 320 new micro-MRI systems were commissioned worldwide, led by North America and Europe which accounted for 62 % of installations. Pharmaceutical companies used micro-MRI notably for longitudinal studies, with over 41 % of micro-MRI labs configuring for repeated imaging of the same animal across multiple time-points. The high cost and technical expertise required mean adoption remains concentrated among top-tier research centres, impacting the speed of proliferation across smaller labs.

Optical : Optical imaging modalities—bioluminescence, fluorescence, photoacoustic—dominate in-vivo small animal imaging, making up approximately 42 % of system installations in 2024. Globally over 1,700 optical imaging systems were in operation that year. Optical systems are favoured for high throughput screening, with around 68 % of academic labs using them for cancer cell detection and monitoring treatment response. The installation cost is typically lower compared with MRI or nuclear systems—around 28 % less on average—and over 54 % of new optical systems deployed in 2024 included automated imaging trays and robotics integration. For the Small Animal Imaging (In-Vivo) Market Report, optical imaging remains the volume leader due to its ease of use and throughput capability.

Nuclear : Nuclear imaging systems (micro-PET, micro-SPECT) accounted for about 29 % of global small animal imaging equipment in 2024, with over 1,150 units installed. These modalities provide the highest sensitivity for molecular imaging applications such as biodistribution and drug/target engagement studies. In 2024 roughly 57 % of nuclear imaging installations were concentrated in the U.S. and Europe. The average tracer usage per study increased by 14 % year-on-year as more complex radiopharmaceuticals entered preclinical pipelines. Nuclear systems are essential in translational research, but require additional infrastructure such as cyclotron or radiochemistry labs, which limit their adoption to well-funded institutions. The Small Animal Imaging (In-Vivo) Market Industry Analysis underlines nuclear modalities as premium but growth-constrained compared to optical systems.

BY APPLICATION

Monitoring Treatment Response : Monitoring treatment response was responsible for approximately 28 % of all small animal imaging applications in 2024. More than 3,600 studies globally used in-vivo imaging platforms to assess therapeutic efficacy, particularly in oncology and immunotherapy. Approximately 64 % of such studies utilised optical or nuclear imaging to measure tumour size reduction or metabolic change, while 22 % used micro-MRI for volumetric analysis. The average study duration extended to 16 weeks for longitudinal imaging of the same cohort. For the Small Animal Imaging (In-Vivo) Market Forecast, treatment response monitoring remains the backbone of modality demand and drives system upgrades and service contracts.

Bio-distribution : Bio-distribution studies accounted for around 31 % of application share in 2024, representing more than 4,000 drug-delivery research programmes globally. Imaging systems tracked tracer movement and accumulation in animal models for over 52 % of biotech and pharmaceutical companies using in-vivo platforms. Nuclear imaging contributed 27 % of bio-distribution applications due to its high sensitivity, while optical systems covered 49 % of the remainder. The average number of animals imaged per experiment increased by 13 % in 2024 as regulatory scrutiny intensified. The Small Animal Imaging (In-Vivo) Market Industry Analysis points to growth in this segment due to expanding complex biologics pipelines.

Determining Drug/Target Engagement : Approximately 15 % of small animal imaging applications in 2024 focused on drug/target engagement, involving over 1,900 studies globally. These applications required high-resolution and high-sensitivity modalities, with micro-PET representing 35 % and micro-MRI representing 31 % of deployments in this category. The average imaging session lasted 75 minutes, and roughly 41 % of labs used dual-modality platforms to capture both functional and anatomical data. The Small Animal Imaging (In-Vivo) Market Research Report highlights this segment as critical for precision medicine development and translation to human trials.

Cancer Cell Detection : Cancer cell detection accounted for about 14 % of applications in 2024, with over 1,800 imaging studies documented globally. Optical imaging was used in 58 % of these studies for early tumour detection and fluorescent marker tracking, while nuclear imaging accounted for 29 %. The number of small animal imaging labs dedicated to oncology increased by 17 % from 2022 to 2024. Imaging throughput improved by 21 % as new multiplex tracers enabled simultaneous detection of multiple biomarkers. The Small Animal Imaging (In-Vivo) Market Trends show oncology continues to drive demand for high-end imaging systems.

Biomarkers : Biomarker imaging represented approximately 8 % of application volume in 2024, with around 1,000 experiments focused on imaging biomarker expression and distribution in vivo. Micro-MRI and optical modalities each accounted for about 43 % of the installations used in this segment. The average study size was 56 animals, and about 42 % of these projects were conducted in collaboration with contract research organisations. The Small Animal Imaging (In-Vivo) Market Insights indicate that biomarker research is increasingly dependent on multi-modality imaging and data analytics.

Longitudinal Studies : Longitudinal studies contributed roughly 3 % of overall application count in 2024, equating to over 400 long-term imaging experiments of the same animal cohort. These studies typically spanned 12 to 24 weeks and used MRI or optical imaging more than 71 % of the time. They are essential for chronic-disease models and require imaging systems with high reproducibility and animal handling capabilities. The Small Animal Imaging (In-Vivo) Market Industry Report emphasises that providers offering reliable scheduling and automation features gain advantage in this niche.

Epigenetics : Epigenetics imaging comprised about 1 % of all applications in 2024, involving fewer than 150 studies that examined chromatin-modification events in vivo using high-resolution imaging. Optical and nuclear imaging shared usage roughly equally in this segment. The small sample size reflects the emerging nature of epigenetics in preclinical imaging. Nonetheless, the Small Animal Imaging (In-Vivo) Market Opportunities suggest this segment has high scientific value and potential for growth as instrumentation and molecular probes evolve.

Small Animal Imaging (In-Vivo) Market Regional

Globally, the Small Animal Imaging (In-Vivo) Market Market is led by North America with approximately 36 % of equipment installations, Europe followed by around 27 %, Asia-Pacific at about 22 %, and Middle East & Africa contributing roughly 15 %. Regional adoption rates vary based on research infrastructure, funding intensity, and modality maturity, offering differentiated opportunities for equipment suppliers, service providers and CROs.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America accounted for roughly 36 % to 37 % of global small animal imaging (in-vivo) installations in 2023, with more than 1,600 imaging systems deployed at academic, biotech and pharmaceutical facilities. Within the U.S., over 1,200 installations occurred across 39 states, and approximately 54 % of new purchases in 2024 were optical imaging systems. Canada and Mexico contributed about 8 % of regional installations. The U.S. federal funding for preclinical imaging research climbed by 21 % year-on-year in 2024, supporting both equipment acquisitions and infrastructure build-out. The extensive presence of contract research organisations (CROs) accounts for more than 42 % of new installations, and over 68 % of imaging studies conducted in North America involve longitudinal or drug-distribution imaging. For companies reviewing the Small Animal Imaging (In-Vivo) Market Industry Analysis, North America remains the highest value region with mature demand for modality upgrades, analytics services and lifecycle maintenance.

EUROPE

Europe held about 27 % of global small animal imaging system installations in 2024, with approximately 1,200 systems across research institutes and pharma sites. Germany, the UK and France accounted for more than 62 % of European installations. Optical imaging systems comprised around 47 % of new European purchases in 2024, while nuclear imaging systems made up approximately 24 %. The region saw over 310 new installations in 2024, a 16 % increase from 2023. Government research funding in Europe for preclinical imaging increased by 19 % year-on-year in 2024, and more than 38 % of labs reported retrofits or modality integrations of hybrid imaging platforms. European universities and research hospitals contributed to more than 54 % of application deployments in cancer cell detection and longitudinal imaging. The Small Animal Imaging (In-Vivo) Market Research Report identifies Europe as a market where service contracts and integrated workflows are increasingly important.

ASIA-PACIFIC

Asia-Pacific represented around 22 % of global small animal imaging installations in 2024, with about 1,000 systems deployed across China, Japan, India and Australia. China alone contributed nearly 48 % of regional installations, with India at 21 % and Japan at 17 %. Optical imaging systems dominated with about 56 % of new installations in the region, while micro-MRI accounted for 14 %. The number of installations in Asia-Pacific increased by approximately 18 % year-on-year from 2023. Governments in the region funded over 120 new radar-supplemented imaging centres for preclinical research, and biotech hubs in India added more than 85 new optical systems in 2024. The Small Animal Imaging (In-Vivo) Market Market Trends emphasize the region as the fastest-growing segment, with strong potential for equipment vendors and CRO-service partners.

MIDDLE EAST & AFRICA

The Middle East & Africa region contributed approximately 15 % of global small animal imaging system installations, with about 700 systems operational in 2024. The United Arab Emirates, Saudi Arabia and South Africa collectively represented nearly 63 % of regional units. Optical imaging systems accounted for 49 % of new deployments in 2024, while nuclear imaging use was around 19 %. The region saw infrastructure investment in more than 40 imaging labs and training centres in 2024, and the number of small animal studies referencing in-vivo imaging in Africa increased by 13 %. For the Small Animal Imaging (In-Vivo) Market Market Opportunities, Middle East & Africa offer expanding but less mature markets where turnkey laboratory solutions and training services are in demand.

List of Top Small Animal Imaging (In-Vivo) Companies

• PerkinElmer, Inc.
• Promega Corporation
• Bruker Corporation
• Thermo Fisher Scientific
• Life Technologies Corporation
• Siemens AG
• Aspect Imaging Ltd.

Top companies by market share:

Bruker Corporation leas the global small animal imaging (in-vivo) market with approximately 18 % of system shipments, followed by PerkinElmer, Inc. with about 15 % share of worldwide installations.

Investment Analysis and Opportunities

Investment in the Small Animal Imaging (In-Vivo) Market Market is being driven by increased funding for preclinical research, equipment refresh cycles and digital-analysis capabilities. In 2024, more than 580 new laboratory expansions included small animal imaging investments globally, with 39 % of those in emerging markets such as Asia-Pacific and Latin America. Service contracts for imaging equipment now represent roughly 28 % of total lifecycle revenue for vendors, reflecting ongoing demand for maintenance and analytics. Automated high-throughput imaging systems reduced workflow time by 24 % in 2024, making them attractive investment opportunities.

New Product Development

Innovation in the Small Animal Imaging (In-Vivo) Market Industry Analysis is focused on automation, high-resolution imaging and hybrid modality platforms. In 2024, over 90 new small animal imaging products were launched globally, of which 38 % were optical imaging systems with high-throughput features. Hybrid systems combining optical and nuclear modalities constituted around 21 % of new releases. Two major vendors introduced micro-MRI systems with 70 % improved spatial resolution, while another delivered automated robotic trays to manage 96 small animals in a single run—reducing operator time by 26 %. In Asia-Pacific, over 35 installations of newly developed dual-modality platforms occurred in 2024. The trend toward digital cloud-enabled imaging data management saw adoption in 29 % of new systems. These developments underline how product innovation is shaping the Small Animal Imaging (In-Vivo) Market Insights.

Five Recent Developments

• In 2023, PerkinElmer launched a high-throughput 2D optical in-vivo imaging system capable of processing 96 animals in one run, increasing throughput by 32 %.
• In 2024, Bruker Corporation acquired a specialised optical imaging company, expanding its product portfolio and increasing its market shipments by 14 %.
• In early 2025, Siemens AG introduced a micro-MRI platform with 35 µm resolution for small animal neuroscience research, reducing scan time by 18 %.
• In 2024, Aspect Imaging Ltd. announced roll-out of portable imaging modules to over 45 universities in Asia-Pacific, accounting for 21 % of regional new installations that year.
• In 2025, Thermo Fisher Scientific introduced AI-driven image-analysis software integrated into small animal imaging systems, automating segmentation and reducing analysis time by 24 %.

Report Coverage

This Small Animal Imaging (In-Vivo) Market Report delivers a full-scale overview of the market by type (micro-MRI, optical, nuclear) and by application (monitoring treatment response, bio-distribution, determining drug/target engagement, cancer cell detection, biomarkers, longitudinal studies, epigenetics). It examines key geographic regions—North America (approx. 36 % share), Europe (27 %), Asia-Pacific (22 %) and Middle East & Africa (15 %)—and provides quantitative data on system installations, modality adoption and application usage. Company profiling includes leading providers such as Bruker (18 % share) and PerkinElmer (15 % share). The report discusses drivers, restraints, opportunities and challenges, with over 12,000 referenced studies, 4,500 systems installed globally as of 2024, and more than 580 lab expansions referenced in 2024 investments.

Small Animal Imaging (In-Vivo) Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 2642.65 Million in 2026
Market Size Value By	USD 5432.26 Million by 2035
Growth Rate	CAGR of 9.43% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Micro-MRI Optical Nuclear By Application : Monitoring Treatment Response Bio-distribution Determining Drug/Target Engagement Cancer Cell Detection Biomarkers Longitudinal Studies Epigenetics
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample